BioCardia, Inc. (BCDA) - Dilution Analysis

10-Q filing | 10.8M shares outstanding

10-K filing | 10.9M shares outstanding

10-Q filing | 10.6M shares outstanding

S-3 filing: This is an S-3 filing for BioCardia, Inc. where selling securityholders may offer or sell up to 549,392 shares of common stock, consisting of 274,696 shares of common stock and 274,696 shares of common stock issuable upon exercise of warrants.

10-Q filing | 5.2M shares outstanding

S-3 filing: BioCardia, Inc. is offering 813,636 shares of common stock through selling securityholders, consisting of 406,818 shares of common stock and 406,818 shares of common stock issuable upon exercise of warrants.

10-K filing | 4.7M shares outstanding

10-Q filing | 4.6M shares outstanding

8-K filing: BioCardia, Inc. completed a registered offering on September 3, 2024, issuing 1,377,990 shares of common stock and pre-funded warrants to purchase up to 1,022,010 shares of common stock, with net proceeds to the company expected to be $6.3 million. ($7.2M proceeds)

S-1/A filing: This S-1/A filing registers the offer and sale of up to 2,439,024 shares of common stock, pre-funded warrants to purchase up to 2,439,024 shares of common stock, and warrants to purchase up to 2,439,024 shares of common stock, along with the shares issuable upon exercise of the pre-funded warrants and warrants.

10-Q filing | 2.1M shares outstanding

S-1 filing: The company is offering common stock, pre-funded warrants, and common warrants in a best efforts offering, with the intention to use the net proceeds from this offering for working capital and general corporate purposes.

8-K filing: BioCardia, Inc. sold 335,112 shares of its common stock for gross proceeds of approximately $1.85 million between April 1, 2024 and June 10, 2024 under its At The Market Offering Agreement. ($1.85M proceeds)

8-K filing: Stock split 1-for-15 | Outstanding: 25,133,093 → 1,825,506

10-Q filing | 25.1M shares outstanding

10-K filing | 26.7M shares outstanding

S-3 filing: BioCardia, Inc. is offering 3,019,466 shares of common stock through selling securityholders, consisting of 2,012,978 shares of common stock and 1,006,488 shares of common stock issuable upon exercise of warrants.

8-K filing: BioCardia, Inc. entered into a Securities Purchase and Registration Rights Agreement for a private placement, selling 2,012,978 shares of common stock at $0.4331 per share (with Dr. Altman paying $0.4625) and warrants to purchase 1,006,488 shares, expecting gross proceeds of approximately $875,000, with the closing expected on February 13, 2024. ($0.88M proceeds)

8-K filing: BioCardia, Inc. entered into a securities purchase agreement to sell 2,000,000 shares of common stock at $0.65 per share in a registered direct offering, with gross proceeds of approximately $1.3 million, expected to close around November 20, 2023. ($1.3M proceeds)

10-Q filing | 21.6M shares outstanding

S-3 filing: BioCardia, Inc. may offer or sell common stock, preferred stock, depositary shares, debt securities, warrants, subscription rights, purchase contracts and units in one or more offerings up to an aggregate amount of $50,000,000.

10-Q filing | 20.4M shares outstanding

8-K filing: BioCardia, Inc. entered into a securities purchase agreement to sell 1,133,141 shares of common stock in a registered direct offering at $2.336 per share, with gross proceeds of approximately $2.6 million. ($2.6M proceeds)

10-Q filing | 20.2M shares outstanding

10-K filing | 20.2M shares outstanding

S-3 filing: BioCardia, Inc. is filing an S-3 to register the offering of 2,122,017 shares of common stock by selling securityholders.

10-Q filing | 17.8M shares outstanding

10-Q filing | 17.7M shares outstanding

10-Q filing | 17.1M shares outstanding

10-K filing | 16.9M shares outstanding

10-Q filing | 16.9M shares outstanding

10-Q filing | 16.9M shares outstanding

10-Q filing | 16.8M shares outstanding

10-K filing | 16.3M shares outstanding

8-K filing: BioCardia, Inc. entered into a securities purchase agreement to sell 2,038,836 shares of common stock at $5.15 per share in a registered direct offering, resulting in gross proceeds of approximately $10.5 million before fees and expenses. ($10.5M proceeds)

8-K filing: BioCardia, Inc. entered into a securities purchase agreement for the sale and issuance of 1,789,474 shares at $4.75 per share, with gross proceeds of approximately $8.5 million, and also entered into a placement agency agreement with A.G.P./Alliance Global Partners for the sale of these shares. ($8.5M proceeds)

10-Q filing | 12.4M shares outstanding

S-3 filing: BioCardia, Inc. files an S-3 to offer common stock, preferred stock, debt securities, depositary shares, subscription rights, purchase contracts for up to $50,000,000.

10-Q filing | 12.4M shares outstanding

8-K filing: BioCardia, Inc. completed a public offering of 5,476,190 shares of common stock at $2.10 per share, resulting in net proceeds of approximately $10.3 million. ($11.5M proceeds)

S-1/A filing: BioCardia, Inc. is offering up to 2,898,550 shares of common stock and pre-funded warrants in a firm commitment underwritten public offering.

S-1/A filing: BioCardia, Inc. is offering 2,380,952 shares of common stock at an assumed price of $4.20 per share, and pre-funded warrants to purchase common stock, in a firm commitment underwritten public offering.

10-Q filing | 6.8M shares outstanding

POS AM filing: This prospectus relates to the offer and sale of 1,928,625 shares of our common stock issuable upon the exercise of outstanding warrants.

10-K filing | 6.8M shares outstanding

S-1 filing: BioCardia, Inc. is offering shares of common stock in a firm commitment underwritten public offering.